On September 23, 2019 Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, reported that it will participate in the 2019 Cantor Global Healthcare Conference in New York, NY (Press release, Halozyme, SEP 23, 2019, View Source [SID1234539724]). Dr. Helen Torley, president and chief executive officer, will represent the company in a question and answer session on Thursday, October 3 at 3:35 p.m. ET / 12:35 p.m. PT.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation can be accessed through the "Investors" section of www.halozyme.com, and a recording will be made available for 90 days following each event. To access a live webcast, please visit Halozyme’s website approximately 15 minutes prior to the presentation to register and download any necessary audio software.

On September 23, 2019 Incyte (Nasdaq:INCY) reported that it will host a conference call and webcast Friday, September 27, 2019, at 11:00 a.m. EDT (5:00 p.m. CEST), to discuss updated pemigatinib data presented at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) 2019 Congress as well as potential future development opportunities for the product candidate (Press release, Incyte, SEP 23, 2019, View Source [SID1234539692]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference call information:

Date and Time: September 27, 2019, 11:00 a.m. EDT (5:00 p.m. CEST)

Domestic Dial-In Number: 877-407-3042

International Dial-In Number: +1 201-389-0864

Conference ID Number: 13694537

The live webcast and slides can be accessed via the Events and Presentations tab of the Investor section of www.incyte.com and will be available for replay for 30 days.

If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is +1 201-612-7415. To access the replay you will need the conference ID number 13694537.

On September 23, 2019 Menarini reported that results from the preclinical study conducted by Menarini Ricerche on MEN1611, a potent and selective orally available phosphatidylinositol 3-kinase (PI3K) inhibitor currently in development for the treatment of breast cancer (Press release, Menarini, SEP 23, 2019, View Source [SID1234539725]). The poster entitled "Characterization of the mechanism of action and efficacy of MEN1611, a novel PI3K inhibitor, in breast cancer preclinical models" will be presented at the ESMO (Free ESMO Whitepaper) Annual Meeting 2019, which will take place in Barcelona on September 27th, during the poster display session scheduled on September 30th (time 12-13).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The PI3K/AKT signaling pathway is often dysregulated in patients with cancer: about 25% of HER2-positive breast cancers carry PIK3CA gene mutations, known to confer resistance to anti-HER2 therapy (i.e. trastuzumab). This study, conducted in several HER2-positive PIK3CA-mutated breast cancer cell lines and patient-derived xenograft models, shows that MEN1611 is able to down-modulate the PI3K/AKT pathway both in vitro and in vivo, and acts synergistically when combined with trastuzumab; moreover, the in vivo efficacy in trastuzumab-resistant models is demonstrated by a long lasting antitumor activity.

These promising preclinical data, provide a strong rationale for MEN 1611 progression in clinical development in breast cancer patients. In this regard, the B-Precise-01 clinical trial (NCT03767335), a multicentre phase Ib study, is currently ongoing in Europe with the aim to evaluate the preliminary clinical activity of MEN1611 in combination with trastuzumab +/- fulvestrant, in patients affected by advanced or metastatic HER2-positive breast cancer, and to select the recommended phase 2 dose

This year Menarini Ricerche will be present at ESMO (Free ESMO Whitepaper) congress also with a dedicated area at the Menarini Silicon Biosystems booth, where it will be possible to get more detailed information about the entire Menarini oncology pipeline and the ongoing clinical trials. Indeed, MEN1611 is part of an innovative pipeline of investigational new drugs focused on precision medicine approaches, that represents the strong and growing commitment of Menarini to oncology and to patients affected by difficult to treat cancers.

On September 23, 2019 Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, reported that it will present several posters highlighting clinical data from three of its ongoing programs for oral paclitaxel and encequidar ("Oral Paclitaxel"; f.k.a Oraxol or oral paclitaxel and HM30181) at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2019 to be held September 27 – October 1, 2019 in Barcelona, Spain (Press release, Athenex, SEP 23, 2019, View Source [SID1234573885]). The posters demonstrate the results from clinical studies of Oral Paclitaxel for patients with a number of advanced solid tumor types as well as in combination with ramucirumab, an anti-VEGFR2 antibody therapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Please see the presentation details below. The abstracts can be found within the conference calendar here.

Poster: 477P
Title: An international randomized cross-over bio-equivalence study of oral paclitaxel + HM30181 compared with weekly intravenous (IV) paclitaxel in patients with advanced solid tumors
Session: Poster Display session
Date: September 28, 2019
Time: 12:00 – 13:00 CEST
Location: Poster Area (Hall 4)
Speaker: Edmond Ang (New Zealand)

Poster: 1733TiP
Title: A pilot study of oral paclitaxel (ORAXOL) in subjects with cutaneous angiosarcomas (KX-ORAX-010)
Session: Poster Display session
Date: September 28, 2019
Time: 12:00 – 13:00 CEST
Location: Poster Area (Hall 4)
Speaker: Herbert H. Loong (Shatin, Hong Kong PRC)

Poster: 800P
Title: A Phase 1b Study of Oraxol in combination with ramucirumab in patients with gastric or esophageal cancers who failed previous chemotherapy
Date: September 29, 2019
Time: 12:00 – 13:00 CEST
Session: Poster Display session
Location: Poster Area (Hall 4)
Speaker: Ming Huang Chen (Taipei City, Taiwan)

The Orascovery platform was initially developed by Hanmi Pharmaceuticals and licensed exclusively to Athenex for all major worldwide territories except Korea, which is retained by Hanmi.

On September 23, 2019 Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, reported that Brian M. Culley, Chief Executive Officer, will be presenting at the 2019 Cell & Gene Meeting on the Mesa on October 3rd, 2019 at 5:00pm Pacific Time at the Park Hyatt Aviara Resort in the BlueRock Therapeutics Ballroom in Carlsbad, CA (Press release, Lineage Cell Therapeutics, SEP 23, 2019, View Source [SID1234539693]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Mesa is a premier conference combining discussions between senior executives and top decision-makers in the industry. The program also includes presentations by the field’s most promising companies in the areas of cell therapy, gene therapy, gene editing, tissue engineering, and broader regenerative medicine technologies and extensive one-on-one partnering capabilities.

A live video webcast of all company presentations will be available at: View Source and will also be published on the conference website shortly after the event.